MYELODYSPLASTIC SYNDROME

This study tests a vaccine designed to protect people who have had a stem cell transplant from a common virus called CMV. The virus can cause serious illness in those with weak immune systems. The vaccine uses a harmless virus to teach the body to fight CMV, aiming to reduce infe…

This study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV can cause serious illness in people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA to help the body build immuni…

This early-phase study tests an experimental drug called INCB057643, given alone or with the standard drug ruxolitinib, in adults with myelofibrosis or other advanced blood cancers. The main goals are to check safety and see if the drug can reduce spleen size, which is a key sign…

This study looks at whether a geriatric assessment—checking thinking, mobility, mood, and nutrition—can help doctors choose the best transplant approach for people aged 60 and older with certain blood cancers. The goal is to lower the risk of serious side effects and improve qual…

This study tests whether adding the drug pomalidomide to standard chemotherapy helps people with a certain type of acute myeloid leukemia (AML) that is linked to prior blood disorders or cancer treatment. About 50 adults with newly diagnosed AML will be randomly assigned to get e…

This study tests an oral medication called emavusertib (CA-4948) in adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or not responded to prior treatments. The goal is to find the safest and most effective dose and to see if th…

This study looks at whether giving palifermin and leuprolide acetate can speed up immune recovery in people who have had a stem cell transplant for blood cancers like leukemia or lymphoma. The transplant uses donor stem cells to replace the patient's blood system. The goal is to …

This study tests whether giving two chemotherapy drugs, clofarabine and melphalan, before a donor stem cell transplant can help prevent leukemia or myelodysplasia from coming back. The trial includes 72 adults whose cancer is in remission or who have high-risk myelodysplastic syn…

This study tests a new treatment called Orca-T for people with advanced blood cancers (like leukemia) who need a stem cell transplant. Orca-T is made from a donor's cells and includes special immune cells to help prevent a serious side effect called graft-versus-host disease (GVH…

This early-phase study tests a new therapy using specially trained immune cells from a donor to target and kill cancer cells in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) whose disease has returned or not gone away after a stem cell transplant. The…

This study tests whether adding another drug (lenalidomide or vorinostat) to the standard chemotherapy azacitidine works better than azacitidine alone for people with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). About 282 adults with thes…

This early-phase study tests the safety and best dose of combining two drugs (RAD001 and PKC412) for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or is hard to treat. The drugs aim to block faulty signals that help cancer cells grow…

This study tests whether adding a second drug (epoetin alfa) to lenalidomide helps people with myelodysplastic syndrome (MDS) and anemia more than lenalidomide alone. About 247 adults with low- or intermediate-risk MDS and low red blood cell counts took part. The main goal was to…

This study is testing a combination of three drugs (azacitidine, venetoclax, and pevonedistat) in adults with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) that is related to prior cancer treatment or other blood disorders. The goal is to find the best dose a…

This program gives patients with certain blood cancers access to Orca-T, a cell therapy, only when their prescribed commercial version is out of specification or expired. The goal is to provide treatment when no other option is available, but it is not a cure and requires ongoing…

This study compares two different chemotherapy combinations (treosulfan-based vs. clofarabine-based) given before a donor stem cell transplant for people with myelodysplastic syndromes or acute myeloid leukemia. The goal is to see which regimen leads to better relapse-free surviv…

This study tests a new drug, seclidemstat, combined with a standard treatment (azacitidine) for people with certain blood cancers (myelodysplastic syndromes and chronic myelomonocytic leukemia). The goal is to find the best dose and see if the combination can shrink or control th…

This study tests an experimental drug called HT-6184 in adults with a low-risk type of bone marrow disorder (MDS) who have anemia that hasn't improved with standard treatments. The goal is to see if the drug can improve blood cell counts and reduce the need for blood transfusions…

This study tests a new combination of three drugs (navitoclax, venetoclax, and decitabine) in about 6 adults with high-risk myelodysplastic syndrome (MDS) that came back or didn't respond to initial treatment. The goal is to find the safest dose and see if the combo can shrink or…

This early-phase study tests a new targeted drug (PVEK) combined with standard chemotherapy for adults with aggressive forms of acute myeloid leukemia and related blood cancers. PVEK works like a smart bomb, attaching to cancer cells and delivering chemotherapy directly to them. …

This study tests whether adding venetoclax to a specific chemotherapy regimen before a donor stem cell transplant can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) live longer without their disease returning. About 116 adults aged 18-70 with pers…

This early-stage study tests a new way to prepare the body for a donor stem cell transplant in people with high-risk leukemia or myelodysplastic syndrome (MDS). It combines targeted radiation (TMLI) with two chemotherapy drugs to kill cancer cells and make room for healthy donor …

This study tests a combination of two drugs, azacitidine and quizartinib, for adults with myelodysplastic syndromes or related blood cancers that have specific gene changes (FLT3 or CBL). The goal is to find the best dose and see how well the drugs control the cancer. About 30 pe…

This early-phase study tests a precise radiation method (IMRT) to deliver total body irradiation while reducing the dose to the lungs. The goal is to prevent lung side effects in 20 adults with acute leukemia or myelodysplastic syndrome undergoing a stem cell transplant. Research…

This early-phase study tests whether adding specially treated immune cells (called veto cells) from a donor can help stem cell transplants work better in people with blood cancers like leukemia or lymphoma. The goal is to help the donor cells grow without causing severe graft-ver…

This study looks at children, teens, and young adults with acute leukemia or myelodysplastic syndrome who need a stem cell transplant. It compares two donor types: a partially matched family donor versus a fully matched unrelated donor. The goal is to see which option leads to fe…

This study tests a combination of two drugs, guadecitabine and atezolizumab, in adults with myelodysplastic syndrome or chronic myelomonocytic leukemia that has spread, returned, or not responded to prior treatment. The goal is to find the best dose and see how well the drugs wor…

This study tests a new way to deliver radiation before a stem cell transplant for people with leukemia or myelodysplastic syndrome (MDS). Instead of radiating the whole body, the new method (TMLI) targets only the bone marrow and lymph nodes, which may reduce damage to healthy or…

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with a chemotherapy drug (azacitidine) can help people with myelodysplastic syndromes (MDS), a bone marrow disorder. About 99 adults with MDS, including those who have not responded to prior tre…

This study tests a specific schedule of chemotherapy drugs (busulfan and fludarabine) followed by a donor stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. After the transplant, a drug called cyclophosphamide is given to help prevent the don…

This study tested a combination of two drugs, vorinostat and azacitidine, in 135 people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to find the safest dose and see how well the drugs work together to stop cancer cell growth. Participants rece…

This study tests a combination of two chemotherapy drugs (CPX-351) plus a targeted antibody (gemtuzumab ozogamicin) in about 50 adults whose acute myeloid leukemia or high-risk myelodysplastic syndrome has returned or not responded to prior treatment. The goal is to see if the co…

This early-stage trial tests a drug called DR-18 in 20 adults whose acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has come back or persists after a stem cell transplant. DR-18 is a modified immune protein designed to boost the body's natural defenses against canc…

This phase 2 trial tests whether adding venetoclax to ASTX727 (a two-drug pill) works better than ASTX727 alone for adults with chronic myelomonocytic leukemia or related bone marrow cancers with excess blasts. About 132 participants will receive either the combination or ASTX727…

This study tests whether adding a drug called cyclophosphamide after a stem cell transplant can lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers or sever…

This study tests an experimental drug called AZD6738 in adults with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease got worse after standard frontline therapy. The main goal is to check the drug's safety and find the right dose. About 52 par…

This study tests two drugs, venetoclax and ASTX727, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who have not had treatment before. The goal is to find the best dose and see how well the combination controls the cancer. About 5…

This early-phase trial tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can help protect the transplant recipient from CMV infection. About 34 people with blood cancers receiving a donor stem cell transplant will have their donors vaccinated before donatio…

This study follows 350 stem cell transplant survivors to see how their heart, lungs, and muscles work together over two years. Researchers measure exercise capacity and other health markers to learn why transplant survivors have a higher risk of heart disease. Participants includ…

This study is testing a new blood test called AlloHeme that can detect tiny amounts of a patient's own cells returning after a bone marrow transplant. The goal is to see if this test can predict a cancer relapse earlier than standard methods. The study involves 307 adults with le…